Tag Archives: Jason Mccarthy
Maxim Group Initiates a Buy Rating on Atossa Therapeutics (ATOS)
Atossa Therapeutics (ATOS – Research Report) received a Buy rating and an $8.00 price target from Maxim Group analyst Jason McCarthy yesterday. The company’s shares closed last Tuesday at $3.91. According to TipRanks.com, McCarthy is a top 100 analyst with
Maxim Group Reiterates a Buy Rating on Biocept (BIOC)
Maxim Group analyst Jason McCarthy reiterated a Buy rating on Biocept (BIOC – Research Report) yesterday and set a price target of $1.00. The company’s shares closed last Tuesday at $0.75. According to TipRanks.com, McCarthy is a top 100 analyst
Maxim Group Keeps a Buy Rating on Applied DNA Sciences (APDN)
Maxim Group analyst Jason McCarthy reiterated a Buy rating on Applied DNA Sciences (APDN – Research Report) yesterday and set a price target of $21.00. The company’s shares closed last Friday at $10.00. According to TipRanks.com, McCarthy is a top
Gilead Sciences (GILD) Gets a Hold Rating from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Gilead Sciences (GILD – Research Report). The company’s shares closed last Friday at $69.53. According to TipRanks.com, McCarthy is a top 100 analyst with an
Maxim Group Sticks to Their Buy Rating for Atossa Therapeutics (ATOS)
In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Atossa Therapeutics (ATOS – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $3.78. According to TipRanks.com, McCarthy is
Maxim Group Releases a Buy Rating on TFF Pharmaceuticals (TFFP)
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to TFF Pharmaceuticals (TFFP – Research Report), with a price target of $12.00. The company’s shares closed last Thursday at $8.62. According to TipRanks.com, McCarthy is
